

Topic
Cases and Deaths
Case Rates
Death Rates
Syndromes
Serotypes
Antibiotic Resistance
Surveillance Report
Year
2019

Dataset version: Mar 2021
Final run: Jun 16, 2021

Note: Click [here](#) to access Surveillance Reports prior to 2019.

Group A <i>Streptococcus</i>	Group B <i>Streptococcus</i>	<i>Haemophilus influenzae</i>	<i>Neisseria meningitidis</i>	<i>Streptococcus pneumoniae</i>
------------------------------	------------------------------	-------------------------------	-------------------------------	---------------------------------

Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network *Streptococcus pneumoniae*, 2019

ABCs Areas: California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (20 county Atlanta area); Maryland (6 county Baltimore area); Minnesota; New Mexico; New York (15 county Rochester and Albany areas and children <5 years in Erie county); Oregon (3 county Portland area); Tennessee (20 counties).

ABCs Population: The surveillance areas represent 34,627,924 persons. Source: National Center for Health Statistics bridged-race vintage 2019 postcensal file.

ABCs Case Definition: Disease is defined as isolation of *S. pneumoniae* from a normally sterile site or detection of pathogen-specific nucleic acid in a specimen obtained from a normally sterile body site, using a validated molecular test in a resident of one of the surveillance areas.

ABCs Methodology: ABCs personnel routinely contacted microbiology laboratories serving acute care hospitals to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Whole genome sequencing (WGS) based characterization was conducted on all pneumococcal isolates, which includes deduction of capsular serotype and minimum inhibitory concentration (MIC) predictions (including PBP typing system for determining beta lactam antibiotic MICs). Conventional MIC testing is conducted on selected strains. Regular laboratory audits assessed completeness of active surveillance and detected additional cases.

Rates of invasive pneumococcal disease were calculated using population estimates from the bridged-race vintage postcensal file. For national estimates, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the U.S. population. Cases with missing data, excluding ethnicity, were multiply imputed using sequential

ABCs Profiles

Race	No.	Rate*
Black	803	13.6
White	2,190	8.6
Other	202	6.0

Topic	Cases		Deaths		
	Age (years)	No.	Rate*	No.	Rate*
<1		55	13.70	4	1.00
1		42	10.40	2	0.49
2-4		54	4.30	1	0.08
5-17		78	1.40	5	0.09
18-34		189	2.30	5	0.06
35-49		472	6.90	37	0.54
50-64		1,044	15.60	112	1.68
65-74		630	19.90	82	2.59
75-84		385	25.20	44	2.88
≥85		246	37.80	49	7.53
Total		3,195	9.20	341	0.98

*Rates are per 100,000 population for ABCs areas

Surveillance Note

Missing race (n=329) data were multiply imputed using sequential regression imputation methods.

Citation

Centers for Disease Control and Prevention. 2019. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Streptococcus pneumoniae*, 2019. www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf

Antibiotic Susceptibility

Category	S*	I†	R‡
TMPsulfa	81.8	11.6	6.6
Erythromycin	69.8	0.0	29.3
Levofloxacin	99.8	0.0	0.0
Penicillin+	96.2	1.6	2.0
Cefotaxime	97.6	1.9	0.3
Tetracycline	87.5	0.0	12.5
Vancomycin	100.0	0.0	0.0

Based on reference lab testing of isolates. *Susceptible; †Intermediate; ‡Resistant based on 2019 CLSI definitions. +Penicillin CLSI breakpoints changed in 2009.

National Estimates of Invasive Disease

Total Cases: 30,300 (9.20/100,000 population)
 Deaths: 3,250 (0.99/100,000 population)

Syndromes

Syndrome	No.	%*
Meningitis	225	7.0
Bacteremia Without Focus	417	13.0
Bacteremia With Pneumonia	2,305	72.1

*Percent of Cases